Jennifer Jimenez
Psychiatric/Mental Health · Union Mills, INNPI 1346586112
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AbbVie at 48.2% of the total. Reporting peaked in 2023 at $16,402 and has fallen 82.3% since, to $2,903 in 2025. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 581 payments — averaging $63.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Johnson & Johnson$6K
- Almatica Pharma LLC$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- plus $5K from 16 others
What the payments were for
- Consulting fees$4,02511%
- Speaking & faculty fees$16,83846%
- Travel & lodging$1,2493%
- Food & beverage$14,38039%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 157 | $17,648 |
| Johnson & Johnson | 57 | $5,772 |
| Almatica Pharma LLC | 8 | $2,275 |
| Alkermes, Inc. | 60 | $1,902 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,871 |
| Neurocrine Biosciences, Inc. | 40 | $1,685 |
| Otsuka America Pharmaceutical, Inc. | 52 | $1,473 |
| Axsome Therapeutics, Inc. | 26 | $1,132 |
| Teva Pharmaceuticals USA, Inc. | 19 | $882 |
| Corium, LLC | 24 | $483 |
| Lundbeck LLC | 25 | $363 |
| Idorsia Pharmaceuticals US Inc | 8 | $296 |
| Harmony Biosciences LLC | 9 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $128 |
| Vanda Pharmaceuticals Inc. | 6 | $113 |
| E.r. Squibb & Sons, L.L.C. | 2 | $106 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $85 |
| Indivior Inc. | 5 | $78 |
| Noven Therapeutics, LLC | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 3 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$15,118
- SPRAVATO$4,595
- LOREEV XR$2,207
- LYBALVI$1,512
- ARISTADA$932
- CAPLYTA$932
- INGREZZA$741
- REXULTI$569
- UZEDY$475
- Auvelity$470
- ABILIFY ASIMTUFII$236
- ABILIFY MAINTENA$236
- INVEGA SUSTENNA$235
- QUVIVIQ$212
- ARISTADA INITIO$120
- INVEGA TRINZA$110
How this compares
$36,613 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 50 | $372,066 |
| Invega SustennaPaliperidone Palmitate | 51 | $181,748 |
| CaplytaLumateperone Tosylate | 73 | $115,103 |
| VraylarCariprazine Hcl | 73 | $109,455 |
| Abilify MaintenaAripiprazole | 23 | $64,630 |
| AristadaAripiprazole Lauroxil | 15 | $42,218 |
| LybalviOlanzapine/Samidorphan Malate | 26 | $38,034 |
| RexultiBrexpiprazole | 23 | $34,716 |
| TrintellixVortioxetine Hydrobromide | 46 | $27,432 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $21,319 |
| BelsomraSuvorexant | 44 | $19,452 |
| QuviviqDaridorexant Hcl | 15 | $12,233 |
| Loreev XrLorazepam | 22 | $8,911 |
| Aripiprazole | 36 | $6,053 |
| Olanzapine | 50 | $5,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,685 | $372,06650 claims |
| Johnson & JohnsonInvega Sustenna | $5,772 | $181,74851 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,871 | $115,10373 claims |
| AbbVieVraylar | $17,648 | $109,45573 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,473 | $99,34646 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,902 | $80,25241 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $128 | $27,43246 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,132 | $21,31920 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $296 | $12,23315 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $2,275 | $9,68259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Union Mills
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
- John WathenEvansville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.